Pacira BioSciences, Inc.

NasdaqGS:PCRX Stock Report

Market Cap: US$1.2b

Pacira BioSciences Valuation

Is PCRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PCRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$94.54
Fair Value
71.3% undervalued intrinsic discount
5
Number of Analysts

Below Fair Value: PCRX ($27.12) is trading below our estimate of fair value ($94.54)

Significantly Below Fair Value: PCRX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PCRX?

Key metric: As PCRX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PCRX. This is calculated by dividing PCRX's market cap by their current revenue.
What is PCRX's PS Ratio?
PS Ratio1.7x
SalesUS$705.85m
Market CapUS$1.22b

Price to Sales Ratio vs Peers

How does PCRX's PS Ratio compare to its peers?

The above table shows the PS ratio for PCRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2x
INVA Innoviva
3.3x11.83%US$1.2b
TLRY Tilray Brands
1.5x4.46%US$1.3b
PAHC Phibro Animal Health
1.2x5.64%US$1.6b
AMPH Amphastar Pharmaceuticals
1.8x4.92%US$1.3b
PCRX Pacira BioSciences
1.7x7.46%US$1.2b

Price-To-Sales vs Peers: PCRX is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (2x).

Price to Sales Ratio vs Industry

How does PCRX's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

66 CompaniesPrice / SalesEstimated GrowthMarket Cap
TEVA Teva Pharmaceutical Industries
1.4x2.35%US$22.86b
VTRS Viatris
0.8x1.16%US$11.61b
AMRX Amneal Pharmaceuticals
1.1x6.78%US$3.14b
PRGO Perrigo
0.7x1.82%US$3.06b
PCRX 1.7xIndustry Avg. 4.7xNo. of Companies66PS0612182430+
66 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: PCRX is good value based on its Price-To-Sales Ratio (1.7x) compared to the US Pharmaceuticals industry average (4.7x).

Price to Sales Ratio vs Fair Ratio

What is PCRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PCRX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.7x
Fair PS Ratio3.1x

Price-To-Sales vs Fair Ratio: PCRX is good value based on its Price-To-Sales Ratio (1.7x) compared to the estimated Fair Price-To-Sales Ratio (3.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PCRX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$27.12
US$29.00
+6.93%
15.11%US$36.00US$23.00n/a5
Sep ’26US$26.67
US$29.00
+8.74%
15.11%US$36.00US$23.00n/a5
Aug ’26US$22.07
US$30.80
+39.56%
22.72%US$44.00US$24.00n/a5
Jul ’26US$23.25
US$30.40
+30.75%
23.32%US$44.00US$24.00n/a5
Jun ’26US$25.84
US$30.40
+17.65%
23.32%US$44.00US$24.00n/a5
May ’26US$26.75
US$36.00
+34.58%
41.04%US$65.00US$21.00n/a6
Apr ’26US$24.07
US$32.00
+32.95%
33.02%US$48.00US$21.00n/a6
Mar ’26US$24.05
US$31.71
+31.87%
36.02%US$50.00US$21.00n/a7
Feb ’26US$26.33
US$27.14
+3.09%
46.66%US$50.00US$11.00n/a7
Jan ’26US$18.84
US$18.13
-3.80%
49.77%US$39.00US$8.00n/a8
Dec ’25US$16.91
US$18.00
+6.45%
50.69%US$39.00US$8.00n/a8
Nov ’25US$16.57
US$18.50
+11.65%
51.49%US$39.00US$8.00n/a8
Oct ’25US$15.30
US$18.38
+20.10%
52.12%US$39.00US$8.00n/a8
Sep ’25US$15.56
US$18.00
+15.68%
53.58%US$39.00US$8.00US$26.678
Aug ’25US$20.75
US$38.44
+85.27%
23.72%US$57.00US$25.00US$22.079
Jul ’25US$28.46
US$44.90
+57.77%
14.89%US$57.00US$36.00US$23.2510
Jun ’25US$30.33
US$44.90
+48.04%
14.89%US$57.00US$36.00US$25.8410
May ’25US$26.95
US$45.30
+68.09%
14.27%US$57.00US$36.00US$26.7510
Apr ’25US$29.15
US$45.30
+55.40%
14.27%US$57.00US$36.00US$24.0710
Mar ’25US$28.86
US$45.56
+57.85%
14.34%US$57.00US$38.00US$24.059
Feb ’25US$31.78
US$47.67
+50.01%
13.63%US$57.00US$38.00US$26.339
Jan ’25US$33.74
US$48.40
+43.45%
13.99%US$58.00US$38.00US$18.8410
Dec ’24US$27.81
US$49.11
+76.60%
13.79%US$58.00US$38.00US$16.919
Nov ’24US$28.31
US$54.67
+93.10%
11.89%US$67.00US$46.00US$16.579
Oct ’24US$30.68
US$55.67
+81.44%
11.95%US$68.00US$46.00US$15.309
Sep ’24US$35.53
US$55.67
+56.68%
11.95%US$68.00US$46.00US$15.569
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
US$29.00
Fair Value
6.5% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/14 17:29
End of Day Share Price 2025/09/12 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pacira BioSciences, Inc. is covered by 33 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anita DushyanthBerenberg
Gary NachmanBMO Capital Markets Equity Research
Tazeen AhmadBofA Global Research